A 72-year-old man with a history of mechanical prosthetic mitral valve replacement is seen in the office for a routine follow-up. He has been taking warfarin for several years. He recently started a new medication for a urinary tract infection. Today, his International Normalized Ratio (INR) is 6.5 (Target: 2.5–3.5), and he notes several new bruises on his arms.
Which of the following best describes the primary mechanism by which his long-term anticoagulant exerts its effect?
The correct answer is:
C) Inhibition of the vitamin K epoxide reductase enzyme
Warfarin is a vitamin K antagonist. Its primary target is the enzyme vitamin K epoxide reductase (VKORC1), which is responsible for recycling oxidized vitamin K back into its active, reduced form (vitamin KH2). Reduced vitamin K is a mandatory cofactor for the gamma-glutamyl carboxylase enzyme. This enzyme adds a carboxyl group to glutamic acid residues on Factors II, VII, IX, and X and the endogenous anticoagulants Proteins C and S. Without this post-translational modification, these factors cannot bind calcium or anchor to phospholipid membranes, rendering them biologically inactive. Because warfarin only inhibits the synthesis of new functional factors and does not affect those already circulating, its clinical effect is delayed until the existing factors decay according to their respective half-lives (Factor VII being the shortest at ~6 hours, and Factor II being the longest at ~60 hours).
Answer choice A: Activation of antithrombin III, is incorrect. This is the mechanism of heparin and low-molecular-weight heparin. These agents work by magnifying the body’s natural anticoagulant, antithrombin III, to neutralize clotting factors already present in the blood.
Answer choice B: Direct inhibition of the active site of Factor Xa, is incorrect. This describes the mechanism of direct oral anticoagulants (DOACs) like apixaban and rivaroxaban. These drugs do not interfere with vitamin K metabolism.
Answer choice D: Irreversible acetylation of COX-1, is incorrect. This is the mechanism of aspirin. Aspirin is an antiplatelet agent that inhibits primary hemostasis, whereas warfarin targets the coagulation cascade (secondary hemostasis).
Answer choice E: Potentiation of Protein C activity, is incorrect. While warfarin actually decreases Protein C levels, leading to a transient prothrombotic state when first started, it does not function as a Protein C agonist.
Key Learning Point
Warfarin prevents the recycling of vitamin K by inhibiting VKORC1, leading to the depletion of functional Factors II, VII, IX, and X. It is monitored using the prothrombin time (PT) and expressed as the INR. Warfarin has numerous drug-drug interactions via the cytochrome P450 system (e.g., antibiotics or amiodarone can increase the INR) and drug-food interactions (e.g., leafy greens rich in vitamin K can decrease the INR).
